Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $24,371.76 in Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Michele Farmer sold 14,952 shares of Pacific Biosciences of California stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.63, for a total value of $24,371.76. Following the completion of the sale, the insider owned 219,092 shares in the company, valued at approximately $357,119.96. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Michele Farmer also recently made the following trade(s):

• On Tuesday, February 17th, Michele Farmer sold 35,215 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.58, for a total value of $55,639.70.

Pacific Biosciences of California Stock Performance

Shares of NASDAQ:PACB opened at $1.61 on Friday. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40. Pacific Biosciences of California, Inc. has a 1 year low of $0.85 and a 1 year high of $2.73. The firm has a market capitalization of $486.07 million, a PE ratio of -0.87 and a beta of 2.27. The business’s 50 day moving average price is $2.01 and its 200-day moving average price is $1.78.

Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%.The firm had revenue of $44.65 million during the quarter, compared to the consensus estimate of $44.60 million. As a group, equities research analysts expect that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year.

Institutional Trading of Pacific Biosciences of California

Several institutional investors have recently made changes to their positions in the company. Koss Olinger Consulting LLC grew its position in Pacific Biosciences of California by 10.0% in the second quarter. Koss Olinger Consulting LLC now owns 3,300,000 shares of the biotechnology company’s stock worth $4,092,000 after acquiring an additional 300,000 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Pacific Biosciences of California by 148.1% in the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 789,271 shares of the biotechnology company’s stock valued at $979,000 after purchasing an additional 471,101 shares during the last quarter. Carret Asset Management LLC purchased a new position in shares of Pacific Biosciences of California during the 2nd quarter worth $391,000. Vestmark Advisory Solutions Inc. increased its position in shares of Pacific Biosciences of California by 89.9% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 1,294,186 shares of the biotechnology company’s stock worth $1,605,000 after purchasing an additional 612,760 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Pacific Biosciences of California by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company’s stock valued at $8,333,000 after buying an additional 401,637 shares during the period.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Genomics sector tailwind — Zacks published a roundup arguing genomics and synthetic-biology stocks deserve portfolio consideration in 2026, supporting longer‑term demand for sequencing platforms like PacBio’s systems. Genomics Stocks That Deserve a Place in Your Portfolio in 2026
• Positive Sentiment: Institutional accumulation — Large funds (ARK, Millennium, Renaissance, Casdin) materially increased or initiated PACB positions in recent quarters, which can provide liquidity support and signal conviction from some professional investors. MarketBeat PACB institutional holdings
• Neutral Sentiment: Upcoming investor event — PacBio will present at the TD Cowen Health Care Conference on March 2; management commentary there could provide updated commercialization or adoption metrics but nothing material has been released yet. PacBio at TD Cowen Conference
• Neutral Sentiment: Analyst mix — Recent notes show modest price‑target upgrades to ~$2.00 from some shops while consensus remains “Hold” with an average PT ~ $2.20; mixed coverage limits a catalytic analyst push. PACB analyst coverage
• Negative Sentiment: Large insider selling — Director/insider Christian O. Henry sold ~472,667 shares across Feb. 17–18 (~$753k proceeds). High‑profile insider sales at this scale often pressure the stock. Christian O. Henry Form 4
• Negative Sentiment: Additional insider exits — Oene Mark Van sold ~184,897 shares (Feb. 17–18) and Michele Farmer sold ~50,167 shares (Feb. 17–18); the combined insider reductions may amplify negative sentiment short‑term. Oene Mark Van Form 4 Michele Farmer Form 4

Analyst Upgrades and Downgrades

PACB has been the subject of several research reports. Piper Sandler upped their price objective on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Zacks Research upgraded Pacific Biosciences of California from a “hold” rating to a “strong-buy” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Thursday, January 22nd. Stephens lifted their price objective on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. Finally, Barclays upped their target price on Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $2.20.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.